Italia markets close in 4 hours 30 minutes

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
55,30+1,71 (+3,19%)
Alla chiusura: 4:00PM EDT
56,79 +1,49 (2,69%)
Preborsa: 06:34AM EDT

CureVac N.V.

Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
http://www.curevac.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno455

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.CEO & Member of Management Board705,82kN/D1970
Mr. Pierre Kemula B.Sc.MD, CFO & Member of Management Board686,61kN/D1974
Ms. Mariola Fotin-MleczekCTO & Member of Management Board549,09kN/D1968
Dr. Igor Splawski M.Sc., Ph.D.Chief Scientific Officer & Member of Management Board462,81kN/D1969
Dr. Antony BlancMD, Chief Bus. Officer & Chief Commercial Officer418,57kN/D1969
Dr. Klaus Edvardsen M.D., Ph.D.Chief Devel. OfficerN/DN/DN/D
Mr. Malte Greune Ph.D.COO & Member of Management BoardN/DN/DN/D
Dr. Sarah FakihVP Corp. Communications & Investor RelationsN/DN/DN/D
Mr. Thorsten SchullerHead of Corp. CommunicationsN/DN/DN/D
Slavica Stevanovic-HeckHead of HRN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidate against COVID-19; CV7202, a prophylactic mRNA-based vaccine, which is in Phase 1 clinical trial for rabies virus glycoprotein; vaccine for lassa yellow fever; vaccine for respirational syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and vaccines for rota, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CV9202 (BI 1361849), a self-adjuvanting mRNA vaccine that is in Phase 1 clinical trial for non-small cell lung cancer, as well as tumor associated antigens and shared neo-antigens. In addition, it is developing protein-based therapies for Cas9 gene-editing, ocular diseases, and lung respiratory diseases, as well as therapeutic antibodies. The company was founded in 2000 and is headquartered in Tübingen, Germany.

Governance aziendale

L'ISS Governance QualityScore di CureVac N.V. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.